TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03890562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
Study: NCT04167696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYAD-02
Description: CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYAD-02
Description: CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYAD-02
Description: CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENDOXAN
Description: administered as preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENDOXAN
Description: administered as preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENDOXAN
Description: administered as preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: administered as preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: administered as preconditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: administered as preconditioning chemotherapy
Study: NCT01122316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
Study: NCT02466334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin-Gene Related Peptide
Description: 1,5 µg/min of IV CGRP over 20 mins

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 ml of normal saline over 20 mins
Study: NCT02821949

Intervention type: BIOLOGICAL
Intervention: PCT dosage
Description: When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
Study: NCT04973813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + Active Choice + action&coping planning (GA+)
Description: Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + Active Choice (GA)
Description: Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline + information (GI)
Description: Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Guideline (G)
Description: Web-based information about the national physical activity guideline.
Study: NCT02588820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (Experimental)
Description: 1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day
Study: NCT04894695

Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers detection in different groups
Description: Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
Study: NCT04512950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
Study: NCT04726670

Intervention type: OTHER
Intervention: Evaluation of postoperative pain
Description: A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit.

Intervention type: OTHER
Intervention: Evaluation of postoperative pain
Description: A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit.
Study: NCT01601132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline
Description: 300mg (80mg/15ml elixir)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
Study: NCT04578483

Intervention type: OTHER
Intervention: PCA group
Description: Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.

Intervention type: OTHER
Intervention: ERDS group
Description: After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
Study: NCT00384657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure.
Study: NCT01782547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
Study: NCT02325986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Study: NCT01788046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously (IV) three times per week.
Study: NCT01691274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, 300 mg, single, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, 300 mg, twice a day, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04895162
Description: Tablets, to be decided, twice a day, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, twice a day, 14 days
Study: NCT03463174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture
Description: Placement of an implant in the mandibular midline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular complete denture
Description: No intervention.
Study: NCT01415895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Clonidine Combination
Description: subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Study: NCT02765269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Pain Management System
Description: A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
Study: NCT02100800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR and CT measurements of emphysema quantification

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MR and CT measurements of emphysema quantification
Study: NCT01364077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg BID titrated to 7.5 mg if tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00844584

Intervention type: PROCEDURE
Group type: OTHER
Intervention: epicardial radiofrequency ablation
Description: epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
Study: NCT00804622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine
Description: daily oral administration,600mg,over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disproxil fumarate
Description: daily oral administration,300mg,over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine plus tenofovir disproxil fumarate
Description: daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
Study: NCT02175628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient.
Study: NCT02869074

Intervention type: GENETIC
Intervention: VWF gene analysis
Description: 52 exons adjacent intronic regions and promotor of VWF will be analyzed
Study: NCT04362319

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire forms
Description: Assessment of demographics, burnout, depression and self-perceived medical errors
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: see detailed protocol description
Study: NCT04239092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description
Study: NCT04239092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: 9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: see detailed protocol description
Study: NCT01662934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I RUNE

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: see detailed protocol description
Study: NCT00830037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron
Description: IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
Study: NCT03650712

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: see detailed protocol description
Study: NCT04239092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.